# OnCo record napabucasin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/napabucasin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "napabucasin" ;
  schema:name "Napabucasin"@en ;
  schema:alternateName "BBI-608"@en, "BBI608"@en ;
  schema:description "Napabucasin, an oral drug marketed as a cancer stemness inhibitor, was tested in 1,134 people with untreated metastatic pancreatic cancer on top of nab-paclitaxel and gemcitabine; survival was identical and the trial was stopped for futility."@en ;
  schema:url <https://onco.cc/drugs/napabucasin/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.eclinm.2023.101897>, <https://clinicaltrials.gov/study/NCT02993731> ;
  onco:status "negative" ;
  onco:modality "Oral small-molecule NQO1-bioactivated reactive oxygen species generator (STAT3 pathway inhibitor)" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/>, <https://onco.cc/cancers/colorectal/> ;
  onco:targets <https://onco.cc/targets/stat3/> ;
  onco:companies <https://onco.cc/companies/sumitomo-pharma/> ;
  onco:terms <https://onco.cc/terms/pancreatic-failed-programmes/> ;
  onco:trials <https://onco.cc/trials/canstem111p/> .